[{"orgOrder":0,"company":"Tenpoint Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"||Adrenergic receptor alpha-2","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tenpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Drops","sponsorNew":"Tenpoint Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tenpoint Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tenpoint Therapeutics","sponsor":"SparingVision","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell & Gene Therapy","year":"2023","type":"Divestment","leadProduct":"SPVN20","moa":"GIRK","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Tenpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tenpoint Therapeutics \/ Tenpoint Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Tenpoint Therapeutics \/ Tenpoint Therapeutics"},{"orgOrder":0,"company":"Tenpoint Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Brimonidine Tartrate","moa":"||Muscarinic acetylcholine receptor M3","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tenpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tenpoint Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Tenpoint Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tenpoint Therapeutics","sponsor":"Visus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Merger","leadProduct":"Brimonidine Tartrate","moa":"||Muscarinic acetylcholine receptor M3","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Tenpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tenpoint Therapeutics \/ Visus Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Tenpoint Therapeutics \/ Visus Therapeutics"},{"orgOrder":0,"company":"Tenpoint Therapeutics","sponsor":"British Patient Capital","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Tenpoint Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Tenpoint Therapeutics \/ British Patient Capital","highestDevelopmentStatusID":"3","companyTruncated":"Tenpoint Therapeutics \/ British Patient Capital"}]